Mallinckrodt lands oral oxycodone, acetaminophen patent; U. of Illinois-Chicago researchers develop nanoscale targeted anti-inflammatory drugs;

> Mallinckrodt ($MNK) collected a patent for its extended-release oral oxycodone and acetaminophen for twice-daily dosing to treat acute pain. It makes use of Depomed's Acuform delivery tech. Release

> Researchers at the University of Illinois at Chicago have developed nanoparticles that target rogue immune cells with anti-inflammatory drugs, while leaving healthy immune cells unharmed. Release

> W.L. Gore touted successful results from its Revise clinical study for its Viabahn Endoprosthesis with Haparin Bioactive Surface. The study showed that it worked better than a percutaneous transluminal angioplasty to treat stenoses or thrombotic occlusions. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.